Form 4: Boston Scientific Executive Arthur C. Butcher Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
EVP Arthur C. Butcher of Boston Scientific Corp. exercised stock options and sold shares of common stock on February 3, 2025, under a pre-established Rule 10b5-1 trading plan.
Summary
- Arthur C. Butcher, an Executive Vice President at Boston Scientific Corp., executed stock options and sold shares of common stock on February 3, 2025.
- The transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
- Butcher exercised options to acquire 6,952 shares at $27.09, 6,176 shares at $24.55, 3,176 shares at $22.71, and 1,009 shares at $17.26.
- He then sold 8,508 shares at a weighted average price of $101.4538 (ranging from $100.895 to $101.86) and 8,805 shares at a weighted average price of $102.1395 (ranging from $101.93 to $102.34).
- Following these transactions, Butcher directly owns 5,502 shares and indirectly owns 13,364 shares through a 401(k) plan.
- He also holds options to purchase 51,940 additional shares at various exercise prices and expiration dates.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, so they don't necessarily indicate a positive or negative outlook on the company's performance. The fact that the executive is exercising options is mildly positive.
Positives
- The transactions were conducted under a pre-established Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
- The executive is exercising options, which suggests confidence in the company's long-term prospects.
Negatives
- The sale of shares by an executive could be perceived negatively by some investors, although it is part of a pre-planned strategy.
Risks
- While the Rule 10b5-1 plan provides some protection, significant sales by executives could still create negative market sentiment.
- Changes in the executive's role or responsibilities could impact future trading activity.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies, often governed by Rule 10b5-1 plans to avoid insider trading concerns. Monitoring these transactions provides insights into executive sentiment and potential market impacts.
Comparison to Industry Standards
- Executive compensation practices, including stock options and sales, are common across the medical device industry.
- Companies like Medtronic, Abbott, and Stryker also have executives who regularly exercise options and sell shares.
- The use of Rule 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations.
Stakeholder Impact
- The transactions could have a minor impact on shareholders due to the potential for slight price fluctuations.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2017-02-22 | First anniversary of grant of option to purchase shares vesting in four equal annual installments. |
| 2017-06-01 | First anniversary of grant of option to purchase shares vesting in four equal annual installments. |
| 2018-02-28 | First anniversary of grant of option to purchase shares vesting in four equal annual installments. |
| 2019-02-15 | First anniversary of grant of option to purchase shares vesting in four equal annual installments. |
| 2024-08-09 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2025-02-03 | Date of the reported transactions (exercise of options and sale of shares). |
| 2026-06-01 | Expiration date of some stock options. |
| 2026-02-22 | Expiration date of some stock options. |
| 2027-02-28 | Expiration date of some stock options. |
| 2028-02-15 | Expiration date of some stock options. |
| 2025-02-04 | Date of the Form 4 filing. |
Keywords
Form 4, Boston Scientific, BSX, Arthur C. Butcher, Stock Options, Rule 10b5-1, Insider Trading, Executive Compensation, Share Sales
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.